These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15463823)

  • 1. Nebulised dornase alpha: adherence in adults with cystic fibrosis.
    Burrows JA; Bunting JP; Masel PJ; Bell SC
    J Cyst Fibros; 2002 Dec; 1(4):255-9. PubMed ID: 15463823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2011 May; (5):CD007923. PubMed ID: 21563162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial.
    Bishop JR; Erskine OJ; Middleton PG
    J Physiother; 2011; 57(4):223-9. PubMed ID: 22093120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2013 Jun; (6):CD007923. PubMed ID: 23737088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
    Wilson CJ; Robbins LJ; Murphy JM; Chang AB
    Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled mannitol for cystic fibrosis.
    Nolan SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis.
    Raynor EM; Butler A; Guill M; Bent JP
    Arch Otolaryngol Head Neck Surg; 2000 May; 126(5):581-3. PubMed ID: 10807324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
    Geller DE
    Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis.
    Voldby C; Green K; Philipsen L; Sandvik RM; Skov M; Buchvald F; Pressler T; Nielsen KG
    J Cyst Fibros; 2021 Nov; 20(6):949-956. PubMed ID: 33619014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the timing of inhaled dornase alfa matter?
    van der Giessen L
    J Cyst Fibros; 2009 Jun; 8 Suppl 1():S6-9. PubMed ID: 19460684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dornase alfa for cystic fibrosis.
    Jones AP; Wallis C
    Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation.
    Bakker EM; Volpi S; Salonini E; van der Wiel-Kooij EC; Sintnicolaas CJ; Hop WC; Assael BM; Merkus PJ; Tiddens HA
    Eur Respir J; 2011 Dec; 38(6):1328-35. PubMed ID: 21737560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.